ARC Centre of Excellence for the Mathematical Analysis of Cellular Systems

  • Stumpf, Michael (Primary Chief Investigator (PCI))
  • Flegg, Jennifer (Chief Investigator (CI))
  • McConville, Malcolm John (Chief Investigator (CI))
  • Read, Gavin (Chief Investigator (CI))
  • Shim, Heejung (Chief Investigator (CI))
  • Coster, Adelle (Chief Investigator (CI))
  • Wilkins, Marc R. (Chief Investigator (CI))
  • Zhang, Wenjie (Chief Investigator (CI))
  • Morris, Richard (Chief Investigator (CI))
  • Beilharz, Traude (Chief Investigator (CI))
  • Lithgow, Trevor (Chief Investigator (CI))
  • McDonald, Mike (Chief Investigator (CI))
  • Nguyen, Lan (Chief Investigator (CI))
  • Simpson, Matthew J (Chief Investigator (CI))
  • Drovandi, Christopher C. (Chief Investigator (CI))
  • Nayak, Richi (Chief Investigator (CI))
  • Araujo, Robyn (Chief Investigator (CI))
  • Wen, Jaiyu (Chief Investigator (CI))
  • Eyras, Eduardo (Chief Investigator (CI))
  • Stone, Eric (Chief Investigator (CI))
  • Baker, Ruth E (Partner Investigator (PI))
  • Curach, Natalie (Partner Investigator (PI))
  • Harrington, Heather (Partner Investigator (PI))
  • Hasenauer, Jan (Partner Investigator (PI))
  • Read, Elizabeth L. (Partner Investigator (PI))
  • Schaerli, Yolanda (Partner Investigator (PI))
  • Schmidt, Simon (Partner Investigator (PI))
  • Stelling, Joerg (Partner Investigator (PI))
  • Stülke, Jörg (Partner Investigator (PI))
  • Ziemert, Nadine (Partner Investigator (PI))

Project: Research

Project Details

Project Description

EI23 round:
The ARC Centre of Excellence for the Mathematical Modelling of Cellular Systems (MACSYS) will develop the mathematical, statistical and computational foundations that are required to transform cell biology into a new discipline that is predictive, quantitative, and reproducible. MACSYS will drive this transformation by developing fundamental theory in applied and computational mathematics to rapidly expand biological knowledge.
Short titleARC Centre of Excellence MACSYS
AcronymMACSYS
StatusActive
Effective start/end date8/02/248/02/30